Nomogram for predicting efficacy of repeated intravesical platelet-rich plasma in non-Hunner-type interstitial cystitis/bladder pain syndrome

Objectives: To investigate influencing factors and establish a nomogram for predicting the short-term efficacy of repeated intravesical platelet-rich plasma (PRP) injections in patients with non-Hunner-type interstitial cystitis/bladder pain syndrome. Methods: We retrospectively analyzed 198 patients who completed 4 intravesical PRP injections between February 2023 and June 2025. Treatment efficacy was defined as a Global Response Assessment score ≥2 at 3 months posttreatment. Predictors were screened using least absolute shrinkage and selection operator regression, and a nomogram was constructed using multivariable logistic regression. Discrimination, calibration, and clinical utility were assessed using the area under the receiver operating characteristic curve (AUC), the Hosmer–Lemeshow test, and decision curve analysis, respectively. Bootstrap resampling (B = 1000) was used for internal validation, and a temporal cohort of 52 patients treated between July and December 2025 was used for validation. Results: Of the 198 patients (mean age 56.3 ± 9.5 years; 90.9% female), 127 (64.1%) achieved effective treatment. Longer disease duration (odds ratio [OR], 1.071, p < 0.001), elevated Self-Rating Anxiety Scale score (OR, 1.055, p = 0.001), and concomitant pelvic floor muscle spasm (OR, 7.147, p < 0.001) were risk factors for ineffectiveness; greater maximum bladder capacity (OR = 0.995, p = 0.019) and higher glomerulation grade (OR, 0.421, p = 0.004) were protective factors. The nomogram achieved an AUC of 0.940, with an optimism-corrected AUC of 0.931 (95% confidence interval, 0.897–0.971) and good calibration (Hosmer–Lemeshow χ 2 = 10.23, p = 0.249). Decision curve analysis showed positive net benefit across threshold probabilities of 0.10–0.70. In the temporal validation cohort, the AUC was 0.910 (95% confidence interval, 0.823–0.997). Conclusions: The nomogram demonstrated favorable predictive performance for short-term PRP efficacy in patients with non-Hunner-type interstitial cystitis/bladder pain syndrome and may serve as a decision-support tool for individualized treatment.

Authors

Institutions

Publication Details

Journal
Current Urology
Published
2026-11-18
DOI
https://doi.org/10.1097/cu9.0000000000000386
Primary Topic
Urinary Bladder and Prostate Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Nomogram for predicting efficacy of repeated intravesical platelet-rich plasma in non-Hunner-type interstitial cystitis/bladder pain syndrome

Jianwei Lv, Xuefan Yang, Weilin Fang, Yin Xu et al.
2 links
Current Urology
Urinary Bladder and Prostate Research
article

Nomogram for predicting efficacy of repeated intravesical platelet-rich plasma in non-Hunner-type interstitial cystitis/bladder pain syndrome

Jianwei Lv, Xuefan Yang, Weilin Fang, Yin Xu, Jin Huang, Xin Song, Ziqin Zhou, Tingting Lv
article en

Abstract

Objectives: To investigate influencing factors and establish a nomogram for predicting the short-term efficacy of repeated intravesical platelet-rich plasma (PRP) injections in patients with non-Hunner-type interstitial cystitis/bladder pain syndrome. Methods: We retrospectively analyzed 198 patients who completed 4 intravesical PRP injections between February 2023 and June 2025. Treatment efficacy was defined as a Global Response Assessment score ≥2 at 3 months posttreatment. Predictors were screened using least absolute shrinkage and selection operator regression, and a nomogram was constructed using multivariable logistic regression. Discrimination, calibration, and clinical utility were assessed using the area under the receiver operating characteristic curve (AUC), the Hosmer–Lemeshow test, and decision curve analysis, respectively. Bootstrap resampling (B = 1000) was used for internal validation, and a temporal cohort of 52 patients treated between July and December 2025 was used for validation. Results: Of the 198 patients (mean age 56.3 ± 9.5 years; 90.9% female), 127 (64.1%) achieved effective treatment. Longer disease duration (odds ratio [OR], 1.071, p < 0.001), elevated Self-Rating Anxiety Scale score (OR, 1.055, p = 0.001), and concomitant pelvic floor muscle spasm (OR, 7.147, p < 0.001) were risk factors for ineffectiveness; greater maximum bladder capacity (OR = 0.995, p = 0.019) and higher glomerulation grade (OR, 0.421, p = 0.004) were protective factors. The nomogram achieved an AUC of 0.940, with an optimism-corrected AUC of 0.931 (95% confidence interval, 0.897–0.971) and good calibration (Hosmer–Lemeshow χ 2 = 10.23, p = 0.249). Decision curve analysis showed positive net benefit across threshold probabilities of 0.10–0.70. In the temporal validation cohort, the AUC was 0.910 (95% confidence interval, 0.823–0.997). Conclusions: The nomogram demonstrated favorable predictive performance for short-term PRP efficacy in patients with non-Hunner-type interstitial cystitis/bladder pain syndrome and may serve as a decision-support tool for individualized treatment.

Current Urology
University of Shanghai for Science and Technology (CN), ShenZhen People’s Hospital (CN), Shanghai University of Medicine and Health Sciences (CN)
Good health and well-being
Urinary Bladder and Prostate Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon